- Shire said it would release additional data on studies on a treatment for rare disease HAE at a conference in Seattle.

Results of the studay evaluating the efficacy and safety of subcutaneously administered lanadelumab would be presented at the American College of Allergy, Asthma & Immunology 2018 Annual Scientific Meeting.

HAE is a rare, genetic and potentially life-threatening disorder that can result in recurrent attacks of oedema -- or swelling -- in various parts of the body.

Data showed that patients treated with lanadelumab 300 mg every two weeks experienced significantly fewer HAE attacksand were less likely to have moderate or severe attacks or use rescue medication.

At 8:08am: [LON:SHP] Shire PLC share price was -9.75p at 4611.25p

Story provided by